Specialty Sterile Compounded Medications for Clinical Trials

The contract focuses on supplying specialty sterile compounded medications for NIH clinical trials, specifically targeting preparations beyond total parenteral nutrition (TPN) and renal replacement therapy (RRT). These preparations include investigational drugs or rare-dose formulations that are not typically available through standard commercial sources, addressing unique and specialized pharmaceutical needs critical to the progression of NIH research. Set to be executed as a subcontract, the work will be performed in Bethesda, with the solicitation and response timelines spanning from May 20 to May 26, 2026. The contract falls under the NAICS code 325412, which pertains to pharmaceutical preparation manufacturing, and is managed by the National Institutes of Health within the Department of Health and Human Services. This initiative supports clinical trials by ensuring access to specialized sterile compounds that facilitate the investigation of novel treatments and dosing regimens.